BioSpace News Archive

Indaptus Therapeutics, Inc., announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and reported financial results for the first quarter ended March 31, 2023.

Clearside Biomedical, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Abeona Therapeutics Inc. announced an oral presentation of additional data from the Company’s pivotal Phase 3 VIITAL™ study evaluating its investigational EB-101 for recessive dystrophic epidermolysis bullosa.

SCYNEXIS, Inc. announced financial results for the first quarter ended March 31, 2023.

Otsuka Pharmaceutical, Co. Ltd. and Lundbeck LLC announce the U.S. Food and Drug Administration has approved the supplemental New Drug Application of REXULTI® for use in the treatment of agitation associated with dementia due to Alzheimer’s disease.

Lipocine Inc. announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Reviva Pharmaceuticals Holdings, Inc. has presented promising preclinical data on the potential of novel serotonin-dopamine stabilizer brilaroxazine for the treatment of psoriasis at the First International Societies for Investigative Dermatology Meeting in Tokyo, Japan, May 10-13, 2023.

Galera Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2023, and provided recent corporate updates.

Virios Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2023.